In Lundbeck we recently initiated a global clinical study, 20058N (Talisman), in Multiple System Atrophy (MSA) at multiple research centers in China and Europe. The results from the study will support MSA drug development, including helping to identify the target population for clinical trials and evaluate treatment effects more consistently, all for the benefit of the patients we are here for.

The Talisman study is an observational, retro-prospective, international, multicenter cohort study, which will explore disease progression (China and EU) and related biomarkers (EU) in a cohort of relatively early stage MSA patients. The Talisman study will help to better understand the epidemiology of the early stages of the disease over a longer period, compared to previous studies.

In China, the study will also confirm the psychometric properties of the Chinese version of the Unified MSA Rating Scale (UMSARS), which may enable China to participate in future global MSA studies on the same timelines as other countries.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

H. Lundbeck A/S published this content on 26 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2022 07:58:08 UTC.